MINIRIN
AssetAlso called desmopressin, desmopressin acetate, STIMATE, DDAVP
Activates vasopressin V2 receptors to increase renal water reabsorption and reduce urine production.
- Stage
- Approved, not sold in the US
- Modality
- Peptide
- Target
- AVPR1A
- 6
- Indications
- 40
- Trials
- 3
- Developers
Approved by the FDA on Sep 16, 2002 (NDA021333). Not sold in the US: Drugs@FDA marks every US product that holds it discontinued. FDA
Indications
6No named disease
Approved, not sold in the US, FDA, Sep 16, 2002
Nocturia
Phase 3, Completed, NCT00477490, clinicaltrials.gov, Nov 12, 2026
Nocturnal enuresis
Phase 3, Completed, NCT01078753, clinicaltrials.gov, Nov 12, 2026
3 more
In the full profile
- Target and mechanism4
- Owner and partners3
- Trials40
- Evidence for its targets4
- Competitors7
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.